Inovio edging forward with COVID-19 vaccine

11 May 2021

US biotech Inovio Pharmaceuticals (Nasdaq: INO) might be behind competitors in the development of a COVID-19 vaccine, but the company has provided a reminder that it is still in the game.

Positive safety, tolerability and immunogenicity data have been announced from Inovio’s placebo-controlled and blinded Phase II segment of its Phase II/III clinical trial in the USA, called INNOVATE, to evaluate INO-4800, the company’s DNA vaccine candidate.

The preliminary results show in a larger population than the Phase I study that INO-4800 was generally safe, well-tolerated and immunogenic in all studied age groups.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK